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Background: People who inject drugs (PWID) are at elevated risk of HIV infection. Data on 
population sizes of PWID living with HIV are needed to inform the implementation of prevention, 
treatment and care programs. We estimated national population sizes of people who recently (past 
12 months) injected drugs living with HIV and evaluated ecological associations with HIV prevalence 
in PWID.  
Methods: We used national data on the prevalence of injecting drug use and of HIV among PWID, 
derived from systematic reviews, to estimate national population sizes of PWID living with HIV. 
Uncertainty was estimated using Monte Carlo simulation with 100,000 draws. We extracted data on 
sample characteristics from studies of HIV prevalence among PWID, and identified national 
indicators that have been observed or hypothesised to be associated with HIV prevalence in PWID. 
We used linear regression to evaluate associations between these variables and HIV prevalence in 
PWID.  
Results: Four countries comprised 55% of the estimated global population of PWID living with HIV: 
Russia (572,500; 95% uncertainty interval (UI) 235,500-1,036,500); Brazil (462,000; 95% UI 283,500-
674,500); China (316,500; 95% UI 171,500-493,500), and the United States (195,500; 95% UI 80,000-
343,000). Greater anti-HCV prevalence and national income inequality were associated with greater 
HIV prevalence in PWID.  
Conclusion: The countries with the largest populations of PWID living with HIV will need to 
dramatically scale up prevention, treatment and care interventions to prevent further increases in 
population size. The association between anti-HCV prevalence and HIV prevalence among PWID 
corroborates findings that settings with increasing HCV should implement effective interventions to 
prevent HIV outbreaks.  The association between income inequality and HIV among PWID reinforces 
the need to implement structural interventions alongside targeted individual-level strategies.  




An estimated 15.6 million (95% uncertainty interval (UI): 10.2-23.7 million) people globally have 
recently (in the past 12 months) injected drugs. Just under one in five people who recently injected 
drugs (18%, or 2.8 million people) are living with HIV infection.1 Although there are effective 
interventions to prevent HIV among PWID, including needle and syringe programs (NSP) and opioid 
substitution therapy (OST),2,3 these are infrequently implemented at sufficient scale,4 and PWID 
living with HIV may experience considerable barriers to accessing antiretroviral treatment.5 As such, 
incident HIV infections continue to occur among PWID. In the last decade, HIV outbreaks among 
PWID have been reported in multiple settings including Athens,6 Glasgow,7 rural United States,8 and 
Bucharest.9  
We estimated national HIV prevalence among people who have recently injected drugs for 108 
countries, identifying wide variation within and between regions.1  Such data provide a baseline to 
assess progress towards the Sustainable Development Goal of ending the AIDS epidemic by 2030.10 
Additional data are needed, however, to understand the relative numbers of people who have 
recently injected drugs living with HIV across countries. Awareness of the population size of people 
who have recently injected drugs living with HIV is critical for planning and monitoring prevention, 
treatment, and care services, and for modelling future HIV burden.  
Although much attention is given to individual-level risk behaviours (e.g. receptive needle sharing) 
for HIV infection, these behaviours are shaped by the risk environment in which injecting drug use 
occurs.11,12 The influence of the risk environment on HIV prevalence among PWID has been widely 
studied, including associations with law enforcement indicators13 and access to needle and syringe 
programs.14 Cross-national ecological studies have examined associations between HIV infection in 
PWID and environmental factors such as hepatitis C prevalence,15 time since implementation of 
harm reduction measures,16 and income inequality.17 Although there are limitations to ecological 
studies, chiefly the inability to infer that observed relationships persist at the individual level,18 they 




health outcomes. The collation of global data on HIV infection among PWID to produce population 
estimates also provided an opportunity to examine associations between a wide range of micro- and 
macro-environmental factors and HIV prevalence in PWID. The aims of this study were to: 
1. Estimate national population sizes of people who recently injected drugs living with HIV 
infection; and 
2. Evaluate associations between risk environment variables and the prevalence of HIV 






As this study includes population health estimates derived from a systematic review, reporting is in 
compliance with the PRISMA guidelines and GATHER statement.19 PWID were defined as people who 
have recently (in the past 12 months) injected illicit drugs or extra-medical pharmaceuticals.  
Population size estimates of PWID living with HIV 
This analysis uses data from systematic reviews on the prevalence of injecting drug use and HIV 
prevalence among PWID. The review protocols were registered with PROSPERO (record numbers 
CRD42016052858 and CRD42016052853) and full methods are published elsewhere.1 The study flow 
diagram is shown in supplementary figure 1. We searched peer-reviewed literature databases 
(Medline, Embase and PsycINFO) and reports from government, intergovernmental and non-
government organisations to identify estimates of the prevalence of injecting drug use or HIV 
prevalence (serologically confirmed) among samples of PWID. There were no language restrictions, 
but searches were restricted to works published since 2008. Searches were conducted in June 2017.  
Eligible data were selected using pre-specified decision rules, including grading of the quality of 
study methods (see supplementary materials). Estimates of the prevalence of injecting drug use that 
were obtained using multi-parameter evidence synthesis, indirect prevalence estimation methods, 
or network scale-up methods were considered the highest quality methods. Multi-site 
seroprevalence studies were the highest quality method for estimating HIV prevalence in PWID. If 
the method used to estimate the prevalence of injecting drug use or HIV prevalence among PWID 
was not provided, the estimate was automatically excluded. Estimates of HIV prevalence based on 
self-reported HIV status or registration data were also excluded. Where multiple estimates were 
available for a country, those with a more highly rated method, and/or more recent data, were 
included in analyses. Multiple estimates for a country were pooled using random effects meta-




prevalence among PWID.1 Studies included in the population size estimates are shown in 
supplementary table 1.  
To estimate population sizes of PWID living with HIV, we first multiplied the prevalence of injecting 
drug use by the prevalence of HIV among PWID. We then multiplied this product by the national 
population size aged 15-64 years20 to obtain the number of PWID living with HIV. Uncertainty 
intervals (UIs) were estimated using Monte Carlo simulation taking 100,000 draws. A binomial 
distribution was used because our parameters of interest were proportions. Estimated sample sizes 
associated with the proportions for simulation input were derived based on the 95% confidence 
intervals (CIs) and standard errors of proportion estimates in each country. The simulated UIs 
incorporated the uncertainty of the estimates of the prevalence of injecting drug use and of the 
estimates of HIV prevalence among PWID. 
Ecological analysis of variables associated with HIV prevalence in PWID 
We modelled across studies to examine risk environment variables associated with HIV prevalence in 
people who have recently injected drugs. Studies were excluded if the study inclusion criteria 
restricted the sample by age (other than restricting the sample to adults), sex, or use of specific 
drugs. For each included study, we extracted data for a pre-defined set of demographic 
characteristics and behaviours of the sample. These were: the proportion of each study sample that 
was female; the mean or median age of the sample; the proportion of the sample with hepatitis C 
virus antibody (anti-HCV; included only serologically confirmed anti-HCV); the mean or median 
duration of injecting drug use within the sample; the proportion of the sample reporting lifetime or 
recent homelessness or unstable housing, incarceration, sex work, injecting risk behaviours, and 
sexual risk behaviours; the proportion of each sample reporting opioids or stimulants as their main 
drug injected; and the year that data collection for the study was completed.  
We further identified national indicators of health, development and inequality that have been 




prevalence in the general population;21 estimated national prevalence of injecting drug use;1 country 
income level (low/middle or high; low- and middle-income countries were combined due to sparse 
data from low-income countries);22 income inequality, as measured by the Gini coefficient (with a 
higher coefficient indicating greater income inequality);23 the Gender Inequality Index;24 the Human 
Development Index (incorporating life expectancy, education and national income);25 national 
incarceration rates;26 and national coverage of NSP (number of needles distributed per PWID 
annually) and OST (number of OST recipients per 100 PWID).4 National indicator data are shown in 
supplementary table 2.  
Generalized linear models were used for the analysis, clustering by country, with the study as the 
unit of analysis and study-level HIV prevalence in PWID as the outcome variable. We had planned to 
examine associations between HIV prevalence and all the study-level variables described above but 
elected not to build models for variables that were available for 25% or fewer of HIV prevalence 
estimates in the database. These variables were lifetime or recent homelessness, incarceration, or 
sex work; and opioids or stimulants as the main drug injected. We elected to use an unweighted 
analysis of world regions to accurately represent the availability of data and not penalise regions 
with more, often higher quality, studies. Where a single study presented multiple estimates (e.g. for 
several cities within a country), all estimates were included separately in models, with adjustment 
for within country data-points dependency in the analyses. Residuals and linear predicted values 
were checked for each analysis.  
We plotted linear regression lines on scatter plots depicting HIV prevalence against each explanatory 
variable; for variables where the model fit was improved after adding the quadratic term (described 
below), we also plotted polynomial lines for trend models of degree two. We presented the R-
squares for the linear trend models and polynomial trend models based on the data-points plotted. 




The outcome variable (HIV prevalence in PWID) was a proportion, and thus logit transformation was 
performed by the formula ln (y / (1 - y)). In the same fashion, exposure variables that were 
proportions were logit transformed. An unadjusted linear model for each exposure variable on the 
logit transformed outcome was fitted first; henceforth ‘linear’ models refer to the linear relationship 
on HIV prevalence on a logit transformed scale. Then, to assess if trends were non-linear, a quadratic 
term was tested by adding the squared exposure variable. Likelihood ratio analyses with chi-square 
tests (type III) were used to evaluate if adding the quadratic term provided a significantly better 
model; if yes, the results for the second model with quadratic term were presented. An exposure by 
region interaction term was entered to test for regional differences in exposures to HIV prevalence 
in PWID.  
General population HIV prevalence was assumed a priori to be an important influence on prevalence 
in PWID; hence, adjusted models included the general population HIV prevalence entered as an 
additional exposure variable. A p-value of <0.003 was used for significance to account for the 







National population sizes of current PWID living with HIV 
Sufficient data to estimate national population sizes of PWID living with HIV were available for 78 of 
179 (44%) countries where evidence of injecting drug use has been identified (Table 1). National 
population sizes of PWID living with HIV are presented in Table 2. Thirty-two countries (40%) have 
estimated populations of fewer than 1,000 PWID living with HIV; an additional 23 countries (29%) 
have fewer than 10,000 PWID living with HIV. Countries with the largest national populations of 
PWID living with HIV are Russia (572,500; 95% uncertainty interval (UI) 235,500-1,036,500), Brazil 
(462,000; 95% UI 283,500-674,500), China (316,500; 95% UI 171,500-493,500), and the United States 
(195,500; 95% UI 80,000-343,000). Together, these countries comprise more than half (55%) of the 
estimated global population of PWID living with HIV (Figure 1).  
Ecological analysis of variables associated with HIV prevalence in PWID 
The database included 626 estimates of HIV prevalence among PWID in 93 countries (52% of 
countries with evidence of injecting drug use). These are summarised in Table 3, with study-level HIV 
prevalence data provided in supplementary Table 3. Plots of HIV prevalence among PWID by 
exposure variables are presented in Figures 2 and 3. For study-level variables, a higher percentage of 
women in the study sample, higher anti-HCV prevalence, and older studies (as indicated by less 
recent year of data collection) were associated with higher HIV prevalence among PWID (Figure 2). 
The scatter plot suggested that anti-HCV prevalence was typically higher than HIV prevalence in any 
given study. Supplementary table 4 provides detail to aid interpretation of the logit transformed 
scatter plots.  
Among the country-level variables tested, higher national prevalence of injecting drug use, higher 
gender inequality, lower Human Development Index, higher incarceration rate, and lower NSP 
coverage were associated with higher HIV prevalence among PWID (Figure 3). A quadratic trend 




association at the higher end of the OST coverage scale, which was driven by a small number of 
data-points from South Asian and Western European countries. HIV prevalence among PWID also 
had quadratic associations with general population HIV prevalence, and income inequality. The 
PWID HIV prevalence increased as the general population HIV prevalence and as income inequality 
increased; this association was not observed at higher values of both variables, where only a small 
number of data-points were available. A box plot suggested higher HIV prevalence in low- and 
middle-income countries as compared to high-income countries (Figure 3).  
Statistical associations between PWID HIV prevalence and the tested variables are presented in 
Table 4. Addition of the squared exposure variables improved the fit for the models that examined 
age of sample, population HIV prevalence, income inequality, and NSP and OST coverage. Models 
with regional interaction terms did not improve the model fit, and therefore interactions terms were 
not included in the final models. Unadjusted analyses showed that higher anti-HCV prevalence in 
PWID, general population HIV prevalence, Gender Inequality Index, and lower Human Development 
Index were all associated with higher HIV prevalence in current PWID. In models adjusted for general 
population HIV prevalence, the statistically significant positive linear association between study-level 
anti-HCV prevalence and PWID HIV prevalence remained. There was a quadratic association 
between income inequality and PWID HIV prevalence after adjusting for general population HIV 
prevalence. The trend suggested increasing PWID HIV prevalence with increasing income inequality 
up to moderately high levels of income inequality, which was not observed thereafter, driven by the 
few data-points with high income inequality but low HIV prevalence among PWID in the Latin 






National estimates of the number of PWID living with HIV were calculated for 78 of 179 countries 
where injecting drug use is known to occur. Four countries accounted for more than half of the 
estimated global population of PWID living with HIV: Russia, Brazil, China, and the United States. In 
ecological analyses, after adjusting for general population HIV prevalence, higher study-level anti-
HCV prevalence and country-level income inequality were associated with higher HIV prevalence in 
PWID. 
Implications 
Previous work has highlighted the potential to use HCV prevalence to estimate HIV epidemic 
potential in PWID,15,27 and increasing HCV prevalence pre-dated a large HIV outbreak in rural PWID 
in the United States.28 The findings presented here provide further support for the contention that 
settings experiencing HCV outbreaks in PWID must take steps to prevent HIV (as well as prevent 
further HCV infection), including scaling up of harm reduction measures as described above.  This is 
of particular importance in areas where HIV prevalence is still low among PWID, but HCV is high and 
harm reduction coverage is very poor, such as in the Middle East and North Africa,1 and in areas that 
are seeing rapid increases in the prevalence of injecting drug use and associated HCV infections, 
such as in many parts of the United States.29,30   
The ecological association between income inequality and HIV prevalence in PWID has previously 
been demonstrated at the national level for European Economic Area countries,17 in US 
metropolitan areas,31 and in communities in Vietnam.32 Our finding suggests that national income 
inequality is an important factor in the HIV epidemic in PWID globally. These findings highlight the 
importance of higher-level contextual factors in potentially influencing HIV prevalence among PWID, 
and the concomitant need to address these through structural interventions and policies. Although 
the causal pathway between income inequality and HIV infection in PWID is unclear, community-




that PWID with the lowest personal incomes in areas with the greatest income inequality are most 
at risk of HIV infection.32 Efforts to reduce income inequality and economic deprivation at the 
structural level while improving the personal economic circumstances of PWID (through increased 
access to employment or social security benefits, for example) may therefore work to reduce HIV 
prevalence in this key population.  
Numerous studies and meta-analyses have identified reductions in HIV prevalence and incidence 
associated with greater coverage of NSP33,34 and OST.2,3,33 A cross-national ecological analysis using 
time since introduction of NSP and OST in European nations reported that nations with each of these 
interventions for a greater number of years had lower HIV incidence in PWID than nations with more 
recent implementation.16 A statistical association between HIV prevalence and current NSP or OST 
coverage was not observed in our ecological analysis, which is likely due to limitations of the analysis 
rather than a true lack of association. Critically, NSP and OST coverage estimates employed in the 
analysis were for the most recent year available, while the study-level HIV prevalence data related to 
all years from 1995 onwards, with most data being collected from 2005 onwards. Outlier 
observations had a clear impact on the modelled relationship between OST coverage and study-level 
HIV prevalence.  
Limitations 
Although there are 197 countries where injecting drug use occurs,1 we were only able to estimate 
the national population size of PWID living with HIV for 78 countries. Data estimating the prevalence 
of injecting drug use and the prevalence of HIV among PWID are scarce or even non-existent for 
many countries. Countries with data may be those with more visible or accessible populations of 
PWID, which may be related to unmeasured factors such as drug law enforcement. When data are 
available, it is often uncertain.1 Highlighting the uncertainty in these data points, we note that the 
estimated number of PWID living with HIV infection in Pakistan is greater than the UNAIDS estimate 




population size estimates of PWID in Brazil1,36,37 due to differences in data sources and decision rules 
around inclusion of estimates in a given exercise.38 There is an enormous need for a greater quantity 
of, and better quality, epidemiological data on both injecting drug use and HIV infection among 
PWID. This is particularly so, but not exclusively, in countries where injecting drug use is an emerging 
behaviour (e.g. in parts of sub-Saharan Africa) and may not previously have been relevant for HIV 
prevention programming.1  
There are important caveats to bear in mind when interpreting the findings of the ecological 
analysis. Several associations that have been repeatedly observed at the individual level (e.g. 
positive correlations between HIV prevalence and age or duration of injecting drug use) were not 
apparent in this analysis. This demonstrates a key limitation of using study-level average indicators 
to assess relationships across studies: an association observed within multiple studies may not be 
the same as the association across studies.18 
Most data points included in the ecological analysis were from studies conducted in Eastern and 
Western Europe, with very little data from Central Asia, Latin America, or Caribbean nations. We did 
not observe any regional differences in the predictors of HIV in people who have recently injected 
drugs. However, we do not have strong evidence as to whether this was due to a lack of regional 
variation, or a lack of data in some regions. Additionally, our analysis did not consider the sample 
size of studies; we explored the option of weighting by sample sizes but several very large studies 
would have dominated the results, masking associations with country-level exposure variables. An 
increase in data availability from diverse world regions would permit better examination of regional 
differences in predictors of HIV in people who have recently injected drugs. 
We were unable to test two key indicators that may influence HIV prevalence among PWID: the 
criminal justice environment, and coverage of ART among PWID living with HIV. Criminalisation of 
drug use appears to be associated with HIV prevalence among PWID,13 but we were unable to 




the study. We were also unable to include study-level recent or lifetime incarceration as a predictor 
variable in our models due to lack of data. We modelled national incarceration rate against HIV 
prevalence in PWID but did not identify any trend. ART coverage could not be included due to a lack 
of data.4 We did not use general population ART coverage data as PWID frequently experience 
significant barriers to accessing treatment for HIV infection,39 and general population data are 
therefore unlikely to reflect coverage in PWID.  
Conclusion 
We estimate that 55% of the world’s estimated population of PWID living with HIV can be found in 
four countries: Russia, Brazil, China, the United States, all of which will need to make concerted 
efforts to reduce this burden. Only 44% of countries where injecting drug use is known to occur had 
sufficient data to estimate national population sizes of PWID living HIV, highlighting the need for 
more and higher quality data to inform our understanding of the size of the global epidemic of HIV 
among PWID. 
HIV prevalence among PWID was associated with anti-HCV prevalence in this population, 
corroborating evidence that HCV prevalence is a key indicator of HIV epidemic potential. Greater 
income inequality was associated with higher HIV prevalence amongst PWID, although the causal 
mechanism of the relationship requires further work to be understood. Reducing the burden of HIV 
infection among PWID will require attention to structural determinants of health in addition to 
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Table 1: Summary of data available to estimate population sizes of PWID living with HIV 
Region N countries 
where IDU is 
known to occur 
N (%) countries 
with estimates of 
IDU prevalence  
N (%) countries 
with estimates of 
HIV prevalence 
among PWID 
N (%) countries with 
estimates of 
population size of 
PWID living with HIV  
Eastern Europe 17 15 (88%) 17 (100%) 15 (88%) 
Western Europe 31 21 (68%) 24 (77%) 20 (65%) 
East and Southeast 
Asia 
16 10 (63%) 11 (69%) 8 (50%) 
South Asia 9 8 (89%) 8 (89%) 6 (67%) 
Central Asia 5 4 (80%) 4 (80%) 4 (80%) 
Caribbean 6 1 (17%) 1 (17%) 1 (17%) 
Latin America 19 5 (26%) 8 (42%) 4 (21%) 
North America 2 2 (100%) 2 (100%) 2 (100%) 
Pacific Islands 15 0 (0%) 3 (20%) 0 (0%) 
Australasia 2 2 (100%) 2 (100%) 2 (100%) 
Sub-Saharan Africa 36 12 (33%) 13 (36%) 10 (28%) 
Middle East and 
North Africa 
21 3 (14%) 15 (71%) 3 (14%) 
Global 179 83 (46%) 108 (60%) 78 (44%) 
Notes: IDU: injecting drug use. PWID: people who inject drugs. Percentages use the number of countries 






Table 2: National prevalence of injecting drug use, and prevalence and population size of HIV 
infection among people who recently (past 12 months) injected drugs 
 Prevalence of injecting 
drug use  
% (95% CI)* 
HIV prevalence among 
PWID  
% (95% CI)* 
Number of current PWID 
living with HIV (95% UI) 
Eastern Europe    
Armenia                             0.62 (0.41-1.35) 5.4 (2.2-8.5) 500 (<500-1500) 
Azerbaijan                          0.61 (0.49-0.74) 9.7 (5.6-13.8) 4000 (2500-6500) 
Belarus                             0.59 (0.22-0.96) 25.6 (17.9-33.2) 10500 (4000-18500) 
Bosnia & 




Bulgaria                            0.38 (0.30-0.45) 7.0 (3.2-1.1) 1500 (1000-1500) 
Czech Republic                      0.64 (0.61-0.67) 0.3 (0.2-0.4) <500 (<500-<500) 
Estonia                             0.94 (0.69-1.73) 53.4 (44.4-62.5) 4500 (2000-7500) 
Georgia 4.19 (0.48-7.90) 2.2 (1.5-2.9) 2500 (500-5500) 
Hungary                             0.06 (0.03-0.08) 0.2 (0.0-0.4) <500 (0-<500) 
Latvia                              0.92 (0.73-1.17) 26.9 (24.1-29.6) 4000 (3000-5000) 
Lithuania                           0.22 (0.12, 0.34) 8.0 (1.7-14.4) 500 (<500-1000) 
Moldova                             0.40 (0.25-0.54) 29.5 (12.9-46.0) 3500 (1500-6000) 
Poland                           NK 18.0 (15.3-20.9)  NE 
Romania                             0.62 (0.46-0.84) 20.5 (7.0-34.1) 16500 (6500-29500) 
Russian 
Federation                       




Slovakia                            0.49 (0.35-0.89) 0.01 (0.0-0.03) <500 (0-<500) 
Ukraine 0.97 (0.52-1.79) 19.1 (16.1-22.2) 61000 (24500-106000) 
Western Europe    
Albania NK 0.5 (0.0-2.8) NE 
Andorra NK NK NK 
Austria 0.32 (0.22-0.42) 0.6 (0.3-1.0) <500 (<500-<500) 
Belgium 0.35 (0.24-0.49) 4.3 (3.3-5.4) 1000 (500-1500) 
Croatia                             0.23 (0.18-0.29) 0.4 (0.0-0.8) <500 (0-<500) 
Denmark 0.45 (0.35-0.52) 1.3 (0.3-3.6) <500 (0-500) 
England 0.59 (0.55-0.63) 0.8 (0.1-1.5) 1500 (500-3500) 
Finland 0.46 (0.41-0.67) 1.2 (0.5-2.4) <500 (<500-500) 
FYR Macedonia NK NK NK 
France 0.20 (0.16-0.23) 8.7 (5.3-12.1) 7000 (4500-10500) 
Germany 0.24 (0.03-0.45) 4. (2.3-6.4) 6000 (1000-12500) 
Greece 0.07 (0.06-0.09) 6.9 (4.2-9.6) 500 (<500-500) 
Iceland NK NK NK 
Ireland 0.27 (0.20-0.33) 5.8 (4.2-7.4) 500 (500-500) 
Italy 0.83 (0.57-1.14) 6.1 (4.7-7.5) 21000 (13000-30500) 
Luxembourg 0.57 (0.45-0.69) 1.5 (0.5-2.5) <500 (<500-<500) 
Malta NK 0.5 (0.0-1.2) NE 
Monaco NK NK NK 
Montenegro NK 0.2 (0.0-0.6) NE 
Netherlands 0.03 (0.02-0.04) 2.3 (1.9-2.6) <500 (<500-<500) 
Northern Ireland NK NK NK 
Norway 0.24 (0.21-0.29) 0.7 (0.0-1.5) <500 (0-<500) 
Portugal 0.22 (0.19-0.25) 18.0 (15.4-20.6) 3000 (2500-3500) 
San Marino NK NK NK 
Scotland 0.44 (0.38-0.49) 0.8 (0.5-1.3) <500 (<500-<500) 
Serbia 0.49 (0.41-0.58) 0.0 (0.0-<0.1) 0 (0-0) 
Slovenia 0.42 (0.30-0.55) 0.5 (0.1-1.0) <500 (<500-<500) 




 Prevalence of injecting 
drug use  
% (95% CI)* 
HIV prevalence among 
PWID  
% (95% CI)* 
Number of current PWID 
living with HIV (95% UI) 
Sweden 0.13 (0.03-0.62) 0.2 (0.0-0.5) <500 (0-<500) 
Switzerland 0.24 (0.19-0.29) 1.4 (0.6-2.2) <500 (<500-500) 










Cambodia                            0.11 (0.10-0.23) 24.4 (17.0-33.1) 2500 (1000-4500) 
China                               0.25 (0.19-0.31) 12.4 (6.8-17.9) 316500 (171500-493500) 
Hong Kong (China) NK NK NK 
Indonesia 0.11 (0.09-0.13) 44.5 (34.0-55.0) 84500 (61000-111500) 
Japan                               0.47 (0.36, 0.58) NK NK 
Lao PDR                             NK 17.4 (7.8-31.4) NE 
Malaysia                            1.33 (1.11-1.56) 17.8 (16.6-19.1) 50500 (41000-60000) 
Mongolia                            NK NK NK 
Myanmar                             0.48 (0.32-0.65) 23.4 (19.0-27.7) 40500 (26000-57500) 
Philippines                         0.04 (0.03-0.05) 20.3 (13.0-27.6) 5000 (3000-7500) 
Republic of Korea                   NK 0.0 (0.0-<0.1) NE 
Singapore                           NK NK NK 
Taiwan NK 12.4 (8.1-16.8) NE 
Thailand                            0.11 (0.03-0.18) 24.5 (17.4-31.7) 12500 (4500-23500) 
Timor Leste                         0.01 (<0.01-0.02) NK NK 
Viet Nam                            0.25 (0.19, 0.31) 16.6 (13.1-20.1) 26500 (19000-36000) 
South Asia    
Afghanistan 0.80 (0.50-1.09) 4.0 (2.2-5.8) 5500 (3000-9000) 
Bangladesh 0.07 (0.06-0.07) 0.5 (0.2-0.7) 500 (<500-500) 
Bhutan NK NK NK 
India 0.02 (0.01-0.03) 15.6 (12.9-18.2) 30500 (19500-43500) 
Iran 0.28 (0.19-0.37) 14.0 (9.2-18.7) 22000 (13000-33500) 
Maldives 0.60 (0.26-0.94) 0.0 (0.0-<0.1) 0 (0-0) 
Nepal 0.20 (0.19-0.21) 9.6 (6.3-12.9) 3500 (2500-4500) 
Pakistan 0.37 (0.32-0.42) 32.3 (25.5-39.1) 136500 (103500-172500) 
Sri Lanka <0.01 (<0.01-<0.01) 0.0 (0.0-<0.1) 0 (0-0) 
Central Asia    
Kazakhstan                          0.96 (0.64, 1.42) 9.2 (8.0-10.4) 10500 (6500-15000) 
Kyrgyzstan                          0.74 (0.50, 1.11) 12.4 (10.3-14.7) 3500 (2000-5000) 
Tajikistan 0.45 (0.30, 0.66) 27.0 (21.0-33.7) 6500 (3500-9500) 
Turkmenistan                       NK NK NK 
Uzbekistan 0.47 (0.32, 0.70) 7.3 (5.8-9.1) 7000 (4000-10500) 
Caribbean    
Bahamas                             NK NK NK 
Bermuda                                NK NK NK 
Puerto Rico 1.15 (0.77, 1.71) 6.0 (3.7-9.3) 1500 (1000-3000) 
Dominican 
Republic                  
NK NK 
NK 
Haiti                               NK NK NK 
Jamaica                             NK NK NK 
Latin America    
Argentina 0.29 (0.29-0.30) 49.7 (35.4-64.0) 40000 (29000-51500) 
Bolivia NK NK NK 
Brazil 0.67 (0.51, 0.87) 48.0 (18.0-78.0) 462000 (283500-674500) 




 Prevalence of injecting 
drug use  
% (95% CI)* 
HIV prevalence among 
PWID  
% (95% CI)* 
Number of current PWID 
living with HIV (95% UI) 
Colombia NK 4.6 (2.7-6.4) NE 
Costa Rica NK NK NK 
Ecuador NK NK NK 
El Salvador NK NK NK 
Guatemala NK NK NK 
Guyana NK NK NK 
Honduras NK NK NK 
Mexico 0.18 (0.12-0.25) 4.0 (3.0-4.9) 6000 (3500-9000) 
Nicaragua NK 2.4 (0.1-12.9) NE 
Panama NK NK NK 
Paraguay NK 9.4 (3.7-15.0) NE 
Peru NK 13.0 (10.9-15.1) NE 
Suriname NK NK NK 
Uruguay 0.30 (0.10-0.87) 18.5 (16.1-21.0) 1000 (0-3000) 
Venezuela NK NK NK 
North America    
Canada 0.39 (0.31-0.47) 11.3 (8.5-14.2) 14000 (25500-46000) 
United States 1.04 (0.57-1.88) 8.7 (6.8-10.7) 195500 (80000-343000) 
Pacific Islands    
American Samoa NK NK NK 




Fiji NK NK NK 
French Polynesia NK NK NK 
Guam NK NK NK 
Kiribati NK NK NK 
Marshall Islands NK NK NK 
Nauru NK NK NK 
New Caledonia NK NK NK 





Samoa NK 0.0^  NE 
Solomon Islands NK 0.0^  NE 
Tonga NK 0.0^  NE 
Vanuatu NK NK NK 
Australasia    
Australia                           0.60 (0.43-0.76) 1.3 (1.0-1.6) 1000 (1000-1500) 
New Zealand                         0.73 (0.49-0.97) 0.1 (0.0-0.8) <500 (0-<500) 
Sub Saharan 
Africa 
   
Angola NK NK NK 
Benin NK 5.1 (3.2-7.0) NE 
Burkina Faso NK NK NK 
Burundi NK NK NK 
Cameroon NK NK NK 
Cape Verde NK NK NK 
Chad NK NK NK 
Dem. Rep. Congo  0.01 (<0.01-0.40) 13.3 (7.3-21.6) 500 (0-19000) 
Cote d'Ivoire 0.01 (<0.01-0.01) 5.3 (1.1-14.6) <500 (0-<500) 
Djibouti NK NK NK 




 Prevalence of injecting 
drug use  
% (95% CI)* 
HIV prevalence among 
PWID  
% (95% CI)* 
Number of current PWID 
living with HIV (95% UI) 
Gabon NK NK NK 
Gambia NK NK NK 
Ghana NK NK NK 
Guinea NK NK NK 
Kenya 0.12 (0.03-0.20) 42.0 (21.1-62.8) 13000 (4000-24500) 
Liberia NK NK NK 
Madagascar 0.12 (0.02-0.59) 4.8 (0.2-9.4) 500 (0-3500) 
Malawi NK NK NK 
Mali NK NK NK 
Mauritius 0.78 (0.39-1.54) 45.5 (42.4-48.6) 3000 (1000-6000) 
Mozambique 0.20 (0.00-0.41) 46.3 (41.9-50.7) 13500 (0-29000) 
Niger NK NK NK 
Nigeria NK 3.1 (1.8,4.4) NE 
Rwanda 0.03 (0.00-0.07) NK NK 
Senegal NK 9.3 (5.0,15.4) NE 
Seychelles 2.30 (1.54-3.43) 3.8 (2.0-6.4) <500 (<500-<500) 
Sierra Leone 0.04 (0.04-0.04) 8.5 (5.4-12.6) <500 (<500-<500) 
Somalia NK NK NK 
South Africa 0.21 (0.06-0.74) 14.2 (11.1-17.8) 11000 (0-32000) 
Swaziland NK NK NK 
Tanzania 1.24 (0.72-1.76) 28.3 (16.3-40.4) 97000 (47000-163000) 
Togo 0.06 (0.01-0.49) NK NK 
Uganda NK NK NK 
Zambia NK NK NK 
Zimbabwe NK NK NK 
Middle East & 
North Africa 
   
Algeria NK 1.1 (0.0-5.7) NE 
Bahrain NK 4.6 (1.9-9.3) NE 
Cyprus 0.08 (0.04-0.12) 1.2 (0.6-1.7) <500 (<500-<500) 
Egypt NK 2.6 (0.6-4.5) NE 
Iraq NK NK NK 
Israel NK 0.0 (0.0-<0.1) NE 
Jordan NK NK NK 
Kuwait NK NK NK 
Lebanon NK 0.0 (0.0-0.1) NE 
Libya 0.05 (0.01, 0.10) 89.6 (85.8-92.7) 2000 (1000-2500) 






Oman NK 11.8 (5.0-18.6) NE 
Qatar NK NK NK 
Saudi Arabia NK 9.8 (7.0-13.2) NE 
Sudan NK 0.0^ NE 
Syrian Arab Rep. NK 0.0 (0.0-<0.1) NE 
Tunisia NK 3.5 (2.6-4.4) NE 





Yemen NK NK NK 
Population size estimates are rounded to the nearest 500. Where confidence intervals are presented in italics, 




other estimates from countries in that region. * Data originally published in Degenhardt et al., 2017.1 
^Confidence intervals unable to be estimated as no sample size was available. CI: confidence interval. UI: 
uncertainty interval. NE: Injecting drug use has been documented in this country and estimates of HIV 
prevalence among people who inject drugs were located, but no estimates of IDU prevalence were located. 
NK: Injecting drug use has been documented in this country, but no estimates of HIV prevalence among people 
who inject drugs were located. Countries with no reports of injecting drug use identified were excluded from 
this table, including: Greenland, Liechtenstein (Western Europe), North Korea (East and southeast Asia), 
Antigua & Barbuda, Barbados, Cuba, Dominica, Grenada, Saint Kitts & Nevis, Saint Lucia, St Vincent & the 
Grenadines, Trinidad & Tobago (Caribbean), Belize (Latin America), Northern Mariana Islands, Tuvalu (Pacific 
Islands), Botswana, Central African Republic, Comoros, Equatorial Guinea, Eritrea, Guinea-Bissau, Lesotho, 





Figure 1: Estimated national HIV prevalence among people who inject drugs and number of people who inject drugs living with HIV. 
 
Note: HIV prevalence data and global population of PWID living with HIV originally published in Degenhardt et al.1  
55% of estimated 
global population of 




Table 3: Summary of studies included in analysis of demographic and behavioural factors associated with HIV prevalence in PWID 




N participants in 
included studies 
Minimum reported 
HIV prevalence (%) 
Maximum reported 
HIV prevalence (%) 
Eastern Europe 157 18 218479 0.0 64.0 
Western Europe 182 20 277401 0.0 58.1 
East and Southeast Asia 88 11 65903 0.0 55.0 
South Asia 59 8 81043 0.0 59. 
Central Asia 5 3 3595 7.3 27.0 
Caribbean 1 1 315 6.0 6.0 
Latin America 8 4 4167 2.0 18.5 
North America 58 2 35814 0.5 25.7 
Pacific Islands 0 - - - - 
Australasia 11 2 18000 0.2 4.0 
Sub-Saharan Africa 30 12 13742 1.4 87.5 
Middle East and North Africa 27 9 21481 0.0 87.1 




Figure 2: Associations of study-level demographic and behavioural profiles of PWID with HIV 
prevalence in PWID 
 




Figure 3: Associations of environmental variables and HIV prevalence in PWID 
 
 




Table 4: Ecological analysis of study-level and country-level associations with HIV prevalence in PWID 
Models of HIV prevalence in current PWID 
N* 
Unadjusted models Adjusted for population HIV prevalence 
β SE 95% CIs p β SE 95% CIs p 
Study-level exposure variables                   
Percentage of sample female 619 0.17 0.07 (0.04,0.31) .012 0.07 0.06 (-0.06,0.19) .289 
Median/mean age of sample 303 0.00 0.04 (-0.06,0.07) .899 0.03 0.03 (-0.03,0.08) .331 
   Median/mean age of sample in model with quadratic 
term 303 0.47 0.21 (0.05,0.89) .027 0.53 0.20 (0.14,0.92) .007 
    Quadratic term  -- -0.01 0.00 (-0.01,0.00) .024 -0.01 0.00 (-0.01,0.00) .010 
Prevalence of anti-HCV+ 385 0.77 0.12 (0.54,1.00) <.001 0.60 0.11 (0.38,0.81) <.001 
Median/mean duration of injecting 167 -0.04 0.05 (-0.14,0.05) .353 -0.02 0.05 (-0.12,0.09) .772 
Percentage of sample reporting injecting risk behaviours 276 -0.01 0.16 (-0.33,0.30) .940 -0.04 0.16 (-0.36,0.28) .817 
Percentage of sample reporting sexual risk behaviours 165 -0.23 0.15 (-0.53,0.06) .122 -0.14 0.11 (-0.36,0.09) .230 
Year of data collection 626 -0.11 0.04 (-0.19,-0.02) .016 -0.07 0.04 (-0.14,0.01) .075 
Country-level exposure variables                   
Population HIV prevalence 626 0.70 0.09 (0.53,0.87) <.001 -- -- -- -- 
Population HIV prevalence in model with quadratic 
term 626 -0.04 0.30 (-0.62,0.54) .882 -- -- -- -- 
    Quadratic term   -- -0.05 0.02 (-0.09,-0.01) .022 -- -- -- -- 
     Population IDU prevalence 582 0.28 0.23 (-0.16,0.73) .216 0.17 0.16 (-0.15,0.49) .287 
Income inequality (Gini Coefficient) 598 0.11 0.04 (0.03,0.19) .005 0.02 0.03 (-0.05,0.09) .508 
Income inequality in model with quadratic term 598 0.49 0.30 (-0.10,1.08) .105 0.48 0.14 (0.21,0.74) <.001 
    Quadratic term   -- -0.01 0.00 (-0.01,0.00) .175 -0.01 0.00 (-0.01,0.00) <.001 
Gender Inequality Index 610 0.04 0.01 (0.02,0.06) <.001 0.02 0.01 (-0.01,0.04) .127 
Human Development Index 621 -0.05 0.02 (-0.08,-0.02) .002 -0.02 0.02 (-0.05,0.01) .260 
National incarceration rate 624 1.70 1.66 (-1.56,4.96) .308 0.55 1.19 (-1.77,2.88) .641 
Country income level (Low/middle vs high) 626 1.27 0.47 (0.35,2.19) .007 0.61 0.40 (-0.18,1.40) .129 
NSP coverage 523 -0.29 0.23 (-0.73,0.16) .207 -0.28 0.23 (-0.73,0.17) .227 




    Quadratic term   -- -0.20 0.15 (-0.50,0.11) .205 -0.25 0.11 (-0.46,-0.04) .017 
OST coverage 583 0.02 0.25 (-0.46,0.50) .935 0.16 0.16 (-0.15,0.47) .321 
    OST coverage in model with quadratic term 583 -1.60 0.50 (-2.59,-0.62) .001 -0.79 0.71 (-2.19,0.61) .267 
    Quadratic term   -- 0.35 0.09 (0.17,0.52) <.001 0.20 0.13 (-0.05,0.46) .120 
 *Maximum number of data points in each model is 626 (the number of estimates of HIV prevalence among people who inject drugs). SE: standard error. CI: confidence 
interval. Anti-HCV: hepatitis C virus antibody positive. NSP coverage and OST coverage are in hundreds. Adjusted models for each variable are independent and adjusted for HIV 
prevalence only.  
